Analyst Coverage
Audio Archives
Calendar of Events
Corporate Governance
Directions
E-mail Alerts
Earnings Estimates
FAQ
Financial Reports
Fundamentals
Information Request
Investor Kit
Proxy
Press Releases
Product Pipeline
SEC Filings
Services & Contacts
Stock Information
Investor Tool Kit
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet

Investor Relations

Stock Quote
CELG (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$70.72
Change (%) Stock is Down 0.48 (0.67%)
Volume2,803,763
Data as of 05/16/12 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Celgene Corporation and its subsidiaries (collectively "we", "our" or "us") is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Our primary commercial stage products include REVLIMID®, VIDAZA®, THALOMID® (inclusive of Thalidomide Celgene® and Thalidomide Pharmion®), ABRAXANE®, whi... More >>

Recent News
DateTitle 
05/10/12New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma
Consistent progression-free survival improvement shown with continuous lenalidomide therapy in elderly patients not eligible for transplant and as maintenance therapy in patients following autologous stem cell transplant BOUDRY, Switzerland--(BUSINESS WIRE)--May. 10, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from three phase III studies evaluating the use of cont... 
Printer Friendly Version
05/07/12Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel
SUMMIT, N.J.--(BUSINESS WIRE)--May. 7, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the appointment of Thomas M. Moriarty as General Counsel and Corporate Secretary. In this position, he will be responsible for global legal strategy at Celgene and will serve on the company’s Management Committee. Mr. Moriarty joins Celgene from Medco Health Solutions where he directed all legal, regulatory, public policy and corporate governance ... 
Printer Friendly Version
05/04/12Celgene Corporation to Present at Two Upcoming Investor Conferences
SUMMIT, N.J.--(BUSINESS WIRE)--May. 4, 2012-- Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company’s Web site at www.celgene.com. Celgene management will provide an overview of the Company. Tuesday, May 8, 2012 Celgene will present at the Baird 2012 Growth Stock Conference at 12:20 p.m. ET. ... 
Printer Friendly Version
04/26/12Celgene Reports First Quarter 2012 Operating and Financial Results
-- Non-GAAP Net Product Sales of $1.25 Billion, Increased 17 Percent Y/Y -- Non-GAAP Total Revenue of $1.27 Billion, Increased 15 Percent Y/Y -- Non-GAAP Diluted Earnings Per Share of $1.08, Increased 30 Percent Y/Y -- 2012 Revenue and Earnings Guidance Reaffirmed SUMMIT, N.J., Apr 26, 2012 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) reported Non-GAAP net product sales ... 
Printer Friendly Version
More >>
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Celgene Corp. posts new information to the site. Just enter your e-mail address and click Submit.
 
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Q1 2012 Celgene Corp. Earnings Conference Call
TO ACCESS THE SLIDES
CLICK HERE

Webcast - Live
Celgene Corp. at Bank of America Merrill Lynch Health Care Conference
05/17/12 at 11:40 a.m. ET
Celgene Corp. at Bank of America Merrill Lynch Health Care Conference
Thursday, May 17, 2012 11:40 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Featured Reports

2011 Annual epoRrt

2012 Proxy Statement


2012 Proxy Vote

Celgene Corporate Brochure